Elsevier

Clinical Therapeutics

Volume 31, Issue 11, November 2009, Pages 2472-2488
Clinical Therapeutics

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

https://doi.org/10.1016/j.clinthera.2009.11.034Get rights and content

Abstract

Background: Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue that has received marketing approval from the European Commission, is a treatment for type 2 diabetes mellitus (DM) that is administered as a once-daily subcutaneous injection.

Objective: The aim of this review was to summarize the efficacy and safety data published about liraglutide, focusing on data from Phase III clinical trials.

Methods: Relevant English-language publications were identified through a search of MEDLINE and EMBASE (from 1948 to October 2009). The search terms included the following: GLP-1, incretin effect, liraglutide, NN2211, exenatide, sitagliptin, and vildagliptin. Original research papers about liraglutide that were published in peer-reviewed journals were considered.

Results: The literature search identified 39 relevant publications. The efficacy and tolerability of oncedaily liraglutide at doses of 0.6, 1.2, and 1.8 mg for type 2 DM, in combination with, and compared with, other type 2 DM treatments were investigated in the Liraglutide Effect and Action in Diabetes (LEAD) Phase III clinical trial program. In the LEAD studies, consistent reductions in glycosylated hemoglobin (HbA1c) of up to 1.6% were seen with liraglutide, and up to 66% of patients achieved the HbA1c goal of <7%. Fasting and postprandial plasma glucose levels were also consistently reduced across the LEAD trials by up to 43 mg/dL (2.4 mmol/L) and 49 mg/dL (2.7 mmol/L), respectively. Hypoglycemia was reported at a rate of 0.03 to 1.9 events per patient annually. Liraglutide significantly improved β-cell function, as measured by homeostasis model assessment for β-cell function analysis (20%–44%) and by ratios of pro-insulin to insulin (−0.11 to 0.01). Consistent reductions in systolic blood pressure up to 6.7 mm Hg were also observed for liraglutide treatment. Liraglutide treatment, as monotherapy and in combination with oral antidiabetic drugs (OADs), was associated with weight loss of up to 3.24 kg. Overall, liraglutide was well tolerated. Nausea was the most common adverse event observed with liraglutide treatment, reported by 5% to 29% of patients; however, nausea was generally mild and transient.

Conclusion: Once-daily liraglutide was effective and well tolerated when used as monotherapy or in combination with OADs in patients with type 2 DM, and is therefore a promising new treatment option for the management of type 2 DM.

References (81)

  • R DeFronzo et al.

    Reduced insulin secretion/insulin resistance (disposition) index is the primary determinant of glucose intolerance in the prediabetic state: Results from ACT NOW

    Diabetes Care

    (2008)
  • B Glaser et al.

    Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes

    Acta Endocrinol (Copenh)

    (1988)
  • Y Li et al.

    Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function

    Diabetes Care

    (2004)
  • E Standl

    The importance of beta-cell management in type 2 diabetes

    Int J Clin Pract Suppl

    (2007)
  • Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]

    Lancet

    (1998)
  • SE Kahn et al.

    Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;29:356]

    N Engl J Med

    (2006)
  • IM Stratton et al.

    Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study

    BMJ

    (2000)
  • HC Gerstein et al.

    Effects of intensive glucose lowering in type 2 diabetes

    N Engl J Med

    (2008)
  • ES Ford et al.

    Trends in A1c concentrations among US adults with diagnosed diabetes from 1999 to 2004

    Diabetes Care

    (2008)
  • MC Riddle et al.

    The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

    Diabetes Care

    (2003)
  • PS Odegard et al.

    Medication taking and diabetes: A systematic review of the literature

    Diabetes Educ

    (2007)
    PS Odegard et al.

    Medication taking and diabetes: A systematic review of the literature

    Diabetes Educ

    (2007)
  • AE Pontiroli et al.

    Duration of obesity is a risk factor for non-insulin-dependent diabetes mellitus, not for arterial hypertension or for hyperlipidaemia

    Acta Diabetol

    (1998)
  • F Alvarez Guisasola et al.

    Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study

    Diabetes Obes Metab

    (2008)
  • AB Hauber et al.

    Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents

    Diabet Med

    (2009)
  • TM Davis et al.

    Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55)

    Diabetes Care

    (2001)
  • RJ Jarrett et al.

    The Bedford survey: Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics

    Diabetologia

    (1982)
  • RC Turner et al.

    Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

    BMJ

    (1998)
  • A Patel et al.

    Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial

    Lancet

    (2007)
  • M Nauck et al.

    Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

    Diabetologia

    (1986)
  • T Vilsbøll et al.

    Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients

    Diabetes

    (2001)
  • MB Toft-Nielsen et al.

    Determinants of the impaired secretion of glucagonlike peptide-1 in type 2 diabetic patients

    J Clin Endocrinol Metab

    (2001)
  • Y Wang et al.

    Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells

    Endocrinology

    (1995)
  • Y Wang et al.

    Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats

    J Clin Invest

    (1997)
  • L Farilla et al.

    Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetes rats

    Endocrinology

    (2002)
  • J Buteau et al.

    Glucagon-like peptide-1 pre- vents beta cell glucolipotoxicity

    Diabetologia

    (2004)
  • L Farilla et al.

    Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

    Endocrinology

    (2003)
  • M Zander et al.

    Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study

    Lancet

    (2002)
  • MA Nauck et al.

    Normalization of fasting hyperglycaemia by exogenous glucagonlike peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

    Diabetologia

    (1993)
  • J Rachman et al.

    Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

    Diabetologia

    (1997)
  • T Vilsbøll et al.

    Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects

    J Clin Endocrinol Metab

    (2003)
  • Cited by (102)

    • Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review

      2021, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
      Citation Excerpt :

      Bizino et al. (2019) also found similar results on their study [16]. This weight loss effect from GLP-1 RA also demonstrated by other studies [23–25]. Better results were found in exenatide therapy, that significantly reduced body weight, waist circumference, and total body and fat truncal fat mass [26].

    • GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice

      2018, Biochemical and Biophysical Research Communications
      Citation Excerpt :

      To overcome this, the DPP-4 inhibitors and DPP-4 resistant long-acting GLP-1 receptor agonists (GLP-1RAs) have been developed and used worldwide to treat type 2 diabetes and obesity. Recent clinical trials in type 2 diabetic patients have shown that administration of GLP-1RAs is associated with substantial reductions in glycemia, weight, systolic blood pressure (SBP) and cardiovascular events, while with low risk of hypoglycemia [8–11]. Evidence in rodents also suggests that peripheral GLP-1RAs act as trophic agents in the pancreatic β-cell proliferation and neogenesis [5,12].

    • Tirzepatide: A New Generation Therapeutic for Diabetes Type 2

      2023, Endocrine, Metabolic and Immune Disorders - Drug Targets
    View all citing articles on Scopus
    View full text